McKesson (MCK) stock price, revenue, and financials

McKesson market cap is $31.5 b, and annual revenue was $231.05 b in FY 2020

$31.5 B

MCK Mkt cap, 07-May-2021

$62.6 B

McKesson Revenue Q3, 2021
McKesson Gross profit (Q3, 2021)3.2 B
McKesson Gross profit margin (Q3, 2021), %5%
McKesson Net income (Q3, 2021)-6.2 B
McKesson EBIT (Q3, 2021)-7.4 B
McKesson Cash, 31-Dec-20203.6 B
McKesson EV37.4 B

McKesson Revenue

McKesson revenue was $231.05 b in FY, 2020 which is a 7.8% year over year increase from the previous period.

Embed Graph

McKesson Revenue Breakdown

Embed Graph

McKesson revenue breakdown by business segment: 79.4% from U.S. Pharmaceutical and Specialty Solutions, 11.9% from European Pharmaceutical Solutions, 5.2% from Other and 3.6% from Other

McKesson revenue breakdown by geographic segment: 16.6% from Foreign and 83.4% from United States

McKesson Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

208.4b214.3b231.1b

Revenue growth, %

5%3%8%

Cost of goods sold

197.2b202.6b219.0b

Gross profit

11.2b11.8b12.0b

Gross profit Margin, %

5%5%5%

R&D expense

125.0m71.0m96.0m

General and administrative expense

8.1b8.4b9.2b

Operating expense total

10.4b10.9b9.5b

EBIT

762.0m886.0m2.5b

EBIT margin, %

0%0%1%

Interest expense

283.0m264.0m249.0m

Pre tax profit

239.0m610.0m1.1b

Income tax expense

(53.0m)356.0m18.0m

Net Income

297.0m255.0m1.1b

EPS

0.30.25.0

McKesson Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

2.7b3.0b4.0b

Accounts Receivable

17.7m18.2b20.0b

Prepaid Expenses

443.0m529.0m617.0m

Inventories

16.3b16.7b16.7b

Current Assets

37.1b38.5b42.2b

PP&E

2.5b2.5b2.4b

Goodwill

10.9b9.4b9.4b

Total Assets

60.4b59.7b61.2b

Accounts Payable

32.2b33.9b37.2b

Short-term debt

1.1b330.0m1.4b

Current Liabilities

36.7b37.6b42.6b

Long-term debt

6.8b7.3b8.0b

Total Debt

7.9b7.6b9.4b

Common Stock

3.0m3.0m2.0m

Additional Paid-in Capital

6.2b6.4b6.7b

Retained Earnings

13.0b12.4b13.0b

Total Equity

10.1b8.3b5.3b

Debt to Equity Ratio

0.8 x0.9 x1.8 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x

Financial Leverage

6 x7.2 x11.5 x

McKesson Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

297.0m255.0m1.1b

Depreciation and Amortization

951.0m949.0m922.0m

Accounts Receivable

1.2b(967.0m)(2.5b)

Inventories

(458.0m)(368.0m)(376.0m)

Accounts Payable

271.0m2.0b4.0b

Cash From Operating Activities

4.3b4.0b4.4b

Purchases of PP&E

(405.0m)(426.0m)(362.0m)

Cash From Investing Activities

(1.5b)(1.4b)(579.0m)

Short-term Borrowings

(20.7b)(37.3b)(21.4b)

Long-term Borrowings

(2.3b)(1.1b)(298.0m)

Dividends Paid

(262.0m)(292.0m)(294.0m)

Cash From Financing Activities

(3.1b)(2.2b)(2.7b)

Net Change in Cash

(111.0m)309.0m1.0b

Interest Paid

298.0m383.0m235.0m

Income Taxes Paid

144.0m262.0m368.0m

McKesson Ratios

USDFY, 2018

Revenue/Employee

3.6m

Debt/Equity

0.8 x

Debt/Assets

0.1 x

Financial Leverage

6 x

McKesson Operating Metrics

FY, 2017FY, 2018FY, 2019FY, 2020

Customers (Medical-Surgical Solutions)

200 k200 k

Customers (U.S. Pharmaceutical Distribution)

40 k

Distribution Centers (McKesson Canada)

13131515

Distribution Centers (U.S. Pharmaceutical Distribution)

27273030

Participant Pharmacies (European Pharmaceutical Solutions)

6.9 k7.9 k

Participant Pharmacies (International Pharmaceutical Distribution)

5.5 k7 k

Pharmacies Owned (European Pharmaceutical Solutions)

2 k2.2 k

Pharmacies Owned (International Pharmaceutical Distribution)

2.4 k2 k

Pharmacies Owned (Rexall Health)

470450410400

Pharmacies Served (International Pharmaceutical Distribution)

50 k

McKesson Employee Rating

3.84096 votes
Culture & Values
3.5
Work/Life Balance
3.5
Senior Management
3.2
Salary & Benefits
3.6
Career Opportunities
3.3
Source